stockrow
Saturday 7 November 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
- Revenue
- +16.5%
- EPS
- −54.8%
- Free cash flow
- +43.9%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
39.59
6.12
−13.39%
Follow RIGL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
2.86 | 2.21 | 1.35 | 2.12 |
+8 more quarters Free account |
P/S ratio |
3.13 | 2.62 | 1.66 | 2.62 | |
P/FCF ratio |
46.17 | 80.77 | 6.30 | 10.21 | |
P/Operating CF |
26.06 | 23.66 | 182.70 | 35.05 | |
P/B ratio |
2.02 | 1.71 | 1.25 | 1.97 | |
Price to Tangible BV |
2.57 | 2.19 | 1.33 | 2.10 | |
EV/Sales |
2.83 | 2.33 | 1.22 | 2.17 | |
EV/EBITDA |
10.32 | 7.26 | 2.91 | 5.03 | |
EV/Operating CF |
9.08 | 8.12 | 4.62 | 8.43 | |
EV/FCF |
41.85 | 71.82 | 4.63 | 8.45 | |
Quick Ratio |
1.98 | 1.58 | 2.20 | 2.08 | |
Current Ratio |
2.39 | 1.94 | 2.62 | 2.42 | |
Net Debt/EBITDA |
(5.26) | (3.91) | (10.70) | (5.63) | |
Debt/Assets |
0.00% | 0.00% | 2.97% | 4.38% | |
Debt/Equity |
0.00 | 0.00 | 0.04 | 0.06 | |
Asset Turnover |
0.75 | 0.76 | 0.88 | 0.87 | |
Operating CF/Net income |
2.62 | 1.77 | 0.31 | 0.08 | |
Capex/Depreciation |
0.00 | (86.53) | 0.00 | 0.00 | |
Interest Coverage |
66.56 | 30.26 | 8.29 | 13.64 | |
Research and Development Expense of Revenue |
22.59% | 17.74% | 19.85% | 15.31% | |
Selling, General and Administrative Expense of Revenue |
42.93% | 41.47% | 52.11% | 42.97% | |
Intangible Assets out of Total Assets |
0.18 | 0.18 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
6.00% | 8.70% | 5.88% | 3.94% | |
Graham Net Nets |
0.12 | 0.12 | 0.26 | 0.15 | |
Graham Number |
94.89 | 95.51 | 99.04 | 99.56 | |
Earnings Yield |
34.93% | 45.17% | 74.22% | 47.26% | |
Free Cash Flow Yield |
2.17% | 1.24% | 15.88% | 9.79% | |
Revenue per Share |
4.32 | 4.24 | 3.19 | 3.88 | |
Operating CF per Share |
1.85 | 1.65 | 0.15 | 1.22 | |
Capex per Share |
0.00 | (3.79) | 0.00 | 0.00 | |
Free Cash Flow per Share |
1.85 | (2.14) | 0.15 | 1.22 | |
Cash per Share |
5.31 | 5.14 | 7.97 | 8.61 | |
Shareholders Equity per Share |
23.79 | 22.94 | 21.72 | 21.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.79 | 22.94 | 21.72 | 21.76 | |
Free Cash Flow |
34.56 | (39.69) | 2.73 | 21.98 | |
Working Capital |
109.75 | 89.94 | 144.54 | 140.93 | |
Capital Expenditures |
— | (70.35) | — | — | |
Net Current Asset Value |
109.75 | 89.89 | 129.32 | 118.05 | |
EV/EBIT |
10.78 | 7.41 | 2.94 | 5.08 | |
Capex to Sales |
0.00 | 0.89 | 0.00 | 0.00 | |
Price to Operating Income |
11.90 | 8.33 | 4.00 | 6.14 | |
| Other line items | |||||
Average Receivables |
51.19 | 47.97 | 45.75 | 46.69 | |
Average Payables |
7.64 | 5.65 | 4.22 | 5.27 | |
Average Inventory |
14.55 | 12.40 | 8.16 | 8.75 | |
Average Assets |
383.21 | 363.90 | 340.29 | 338.79 | |
Average Common Equity |
281.36 | 253.68 | 209.23 | 197.38 |
Columns are period end dates · fundamentals updated 5 Nov 2026